These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31639831)

  • 21. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
    Veldman A; Hoffman M; Ehrenforth S
    Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
    Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
    Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor V Leiden improves in vivo hemostasis in murine hemophilia models.
    Schlachterman A; Schuettrumpf J; Liu JH; Furlan Freguia C; Toso R; Poncz M; Camire RM; Arruda VR
    J Thromb Haemost; 2005 Dec; 3(12):2730-7. PubMed ID: 16359510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin-bound structures of designed analogs of human fibrinopeptide A determined by quantitative transferred NOE spectroscopy: a new structural basis for thrombin specificity.
    Ni F; Zhu Y; Scheraga HA
    J Mol Biol; 1995 Oct; 252(5):656-71. PubMed ID: 7563081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
    Margaritis P; Roy E; Faella A; Downey HD; Ivanciu L; Pavani G; Zhou S; Bunte RM; High KA
    Blood; 2011 Apr; 117(15):3974-82. PubMed ID: 21325603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies.
    Ferrarese M; Pignani S; Lombardi S; Balestra D; Bernardi F; Pinotti M; Branchini A
    Thromb Res; 2019 Jan; 173():4-11. PubMed ID: 30453126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
    Sehgal A; Barros S; Ivanciu L; Cooley B; Qin J; Racie T; Hettinger J; Carioto M; Jiang Y; Brodsky J; Prabhala H; Zhang X; Attarwala H; Hutabarat R; Foster D; Milstein S; Charisse K; Kuchimanchi S; Maier MA; Nechev L; Kandasamy P; Kel'in AV; Nair JK; Rajeev KG; Manoharan M; Meyers R; Sorensen B; Simon AR; Dargaud Y; Negrier C; Camire RM; Akinc A
    Nat Med; 2015 May; 21(5):492-7. PubMed ID: 25849132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
    Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
    J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
    Nossel HL; Ti M; Kaplan KL; Spanondis K; Soland T; Butler VP
    J Clin Invest; 1976 Nov; 58(5):1136-44. PubMed ID: 993337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiency.
    Pinotti M; Marchetti G; Baroni M; Cinotti F; Morfini M; Bernardi F
    Thromb Haemost; 2002 Aug; 88(2):236-41. PubMed ID: 12195695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X.
    Chafa O; Tagzirt M; Tapon-Bretaudière J; Reghis A; Fischer AM; LeBonniec BF
    Thromb Res; 2009 May; 124(1):144-8. PubMed ID: 19135706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.